Product Name:
RSK1-CT
Product Number:
ab-nk164-3
Target Full Name: Ribosomal S6 protein-serine kinase 1; Ribosomal protein S6 kinase alpha 2
Target Alias: 90 kDa ribosomal protein S6 kinase 1; HU-1; Kinase p90RSK1; KS6A1; KS6AA; MAPKAPK1A; P90RSK1; RPS6KA1; S6K-alpha 1; CCDS284.1; ENSG00000117676
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK164-3
Antibody Target Type: Pan-specific
Protein UniProt: Q15418
Protein SigNET: Q15418
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human RSK1 (RPS6KA1, p90RSK) sequence peptide Cat. No.: PE-01AQO95
Antibody Immunogen Sequence: CSALNSSKPTPQLKPIESSILAQRRVKKLPSTTL
Antibody Immunogen Description: Corresponds to amino acid residues S703 to L734; C-terminus
Production Method: Corresponds to amino acid residues S703 to L734; C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 0.4 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity of a target-sized protein by Western blotting in mouse skeletal muscle, andStrong detection in brain, testes and thymus.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 82-92 kDa.
Antibody Specificity: Very high
Antibody Cross Reactivity: No significant cross-reactivities in diverse mouse tissues and human cell lines, except weak cross-reactivity with ~50 kDa protein in mouse testes and Jurkat cells.
Related Product 1: RSK1-CT blocking peptide
Related Product 2: RSK1-pS221 phosphosite-specific antibody (Cat. No.: AB-PK804)
Related Product 3: RSK1-pS380 phosphosite-specific antibody (Cat. No.: AB-PK805)
Related Product 4: RSK1-pT573 phosphosite-specific antibody (Cat. No.: AB-PK806)
Related Product 5: RSK1-pY220+pS221 phosphosite-specific antibody (Cat. No.: AB-PK807)
Related Product 6: RSKSubtide - RSK1_d1 (RPS6KA2) protein kinase substrate peptide
Related Product 7: RPS6 (230-238) KinSub - 40S ribosomal protein S6 (K230-R238, human) peptide; p70S6K protein kinase substrate peptide
Related Product 8: RPS6 (230-239) KinSub - 40S ribosomal protein S6 (K230-A239, human) peptide; RSK protein kinase substrate peptide
Scientific Background: RSK1 (RPS6KA1) is a protein-serine/threonine kinase of the AGC group and RSK family, which features two kinase catalytic domains on the same polypeptide chain. This kinase is highly expressed and widely distributed in most tested human tissues. RSK1 transcript is present in lymphocytes, skeletal muscle, liver, and adipose tissue. RSK1 is activated by phosphorylation at S363, S380 and T573. Phosphorylation at S221 by PDK1 is required for increased phosphotransferase activity, but is insufficient by itself. Phosphorylation at S154 induces interaction with 14-3-3 and inhibits catalytic activity. RSKs are implicated in the activation of the mitogen-activated kinase (MAPK) cascade and the stimulation of cell proliferation and differentiation. RSK1 forms a complex with either ERK1 or ERK2 in quiescent cells, and phosphorylation of S732 in response to mitogenic stimulation of cells permits dissociation of RSK-ERK complexes. RSK1 is known phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway -- a pro-growth/anti-apoptotic pathway, as it will activate CREB, which in turn will upregulate expression of cyclin-D and c-Myc. Activation of this pathway is common in various types of tumours. RSK1 may be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. Abnormal activation of RSK1 expression has been linked to many human diseases, including breast and prostate cancers. Inhibition of RSK signalling enhances the effects of enzalutamide prostate cancer therapy.
